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Correcting bias due to missing stage data in the non-parametric estimation of 
stage-specific net survival for colorectal cancer using multiple imputation 
 
Abstract 
Background: Population-based net survival by tumour stage at diagnosis is a key 
measure in cancer surveillance. Unfortunately, data on tumour stage are often 
missing for a non-negligible proportion of patients and the mechanism giving rise to 
the missingness is usually anything but completely at random. In this setting, 
restricting analysis to the subset of complete records gives typically biased results. 
Multiple imputation is a promising practical approach to the issues raised by the 
missing data, but its use in conjunction with the Pohar-Perme method for estimating 
net survival has not been formally evaluated.  
Methods: We performed a resampling study using colorectal cancer population-
based registry data to evaluate the ability of multiple imputation, used along with the 
Pohar-Perme method, to deliver unbiased estimates of stage-specific net survival 
and recover missing stage information. We created 1000 independent data sets, 
each containing 5000 patients. Stage data were then made missing at random under 
two scenarios (30% and 50% missingness).     
Results: Complete records analysis showed substantial bias and poor confidence 
interval coverage. Across both scenarios our multiple imputation strategy virtually 
eliminated the bias and greatly improved confidence interval coverage. 
Conclusions: In the presence of missing stage data complete records analysis often 
gives severely biased results. We showed that combining multiple imputation with the 
Pohar-Perme estimator provides a valid practical approach for the estimation of 
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stage-specific colorectal cancer net survival. As usual, when the percentage of 
missing data is high the results should be interpreted cautiously and sensitivity 
analyses are recommended.  
 
Key words: cancer, informative censoring, multiple imputation, net survival, Pohar-
Perme estimator, uncongeniality. 
 
  
1. Introduction 
Net survival, namely the probability of survival in the hypothetical situation where 
patients can only die of the disease under investigation, plays a fundamental role in 
cancer survival studies. Its estimation poses several challenges. First, it requires the 
handling of competing mortality risks because death can occur for reasons other than 
cancer. Secondly, these competing risks are almost always mutually correlated, 
which results in an informative censoring mechanism that cannot be safely ignored 
[1]. In addition, analyses may be further complicated by the unavailability or 
unreliability of information on cause of death. In population-based cancer registry 
studies this is usually handled via a so-called relative survival approach, which 
consists in estimating the excess mortality experienced by the cancer patients as 
compared to the mortality expected in a comparable general population. The 
advantage of this approach is that it does not require an accurate recording of the 
cause of death for the cancer patients. 
Various methods have been devised for the estimation of net survival in the 
relative survival setting [1,2,3]. Pohar Perme et al. [1] proposed an unbiased non-
parametric estimator that adjusts for informative censoring via inverse probability 
weighting. Danieli et al. [4] and Roche et al. [5] recommended this method especially 
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for routine net survival estimations by cancer registries. This estimator is particularly 
convenient when the analyst is not interested in evaluating covariate effects but 
merely seeks to estimate a summary measure (e.g. net survival or cumulative excess 
hazard) for all patients or for groups of patients. For instance, it can be used to 
estimate net survival by tumour stage at diagnosis, a measure which is of great 
importance for cancer surveillance and health planning and evaluation [6,7].  
Although completeness of stage has considerably improved in recent years in 
many cancer registries, stage is often unavailable for a non-trivial number of patients. 
For example, in a recent series of papers by the International Cancer Benchmarking 
Partnership [6,7] the authors excluded from the analysis some of the cancer 
registries because of their high percentage of missing stage information. In particular, 
Maringe et al. [6] focused on colorectal cancer survival and excluded the registries 
that had less than 50% of patients with recorded stage data in the study period. 
Unfortunately, missingness on tumour stage is typically not completely at random. 
For example, older and more frail patients with relatively poor prognosis may be less 
likely to receive a thorough staging investigation [8]. Restricting the analysis to 
patients with complete records can lead to misleading results [8,9]. This situation is 
exacerbated when calculating net survival, where complete records analysis is only 
valid when data are missing completely at random. While multiple imputation has 
been successfully applied to parametric relative survival settings [8,9], to the best of 
our knowledge, no work has yet been published on the non-parametric estimation of 
stratum-specific (e.g. stage-specific) net survival when the stratification variable is not 
fully observed. 
In this paper we report a resampling study from an extract of a population-based 
cancer registry data set. The aim is to evaluate the ability of multiple imputation 
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[10,11], used in conjunction with the Pohar-Perme estimator of net survival, to reduce 
bias and improve confidence interval coverage when a key covariate (tumour stage) 
is missing at random.   
Our proposed approach combines parametric imputation with a non-parametric 
estimator of net survival. This makes it an uncongenial imputation strategy [12]. 
Several authors [13,14] have argued that, unless the imputation model is grossly 
misspecified, uncongenial strategies like ours may perform better and be more robust 
than methods where missingness and estimation are handled in a “single step”. 
However, it is important to evaluate the performance of our approach empirically; this 
is especially the case as it is unclear how to perform an efficient “single step” analysis 
for the non-parametric Pohar-Perme estimator.  
The paper is structured as follows. We start by briefly introducing the Pohar-
Perme estimator. Next, we describe the resampling design and the analysis setting. 
We then report our results and conclude with a discussion of our findings. 
 
2. Methods 
 
2.1 The Pohar-Perme estimator 
In the relative survival setting the total hazard at time t, here denoted by 𝜆∗(𝑡), is 
usually decomposed as 
                                         𝜆∗(𝑡)  =  𝜆𝐸(𝑡)  + 𝜆𝑃(𝑡)                                   (1) 
where 𝜆𝐸(𝑡) is the excess or cancer-related hazard and 𝜆𝑃(𝑡) represents the 
background or expected hazard. Two data sources are then used: 𝜆∗(𝑡) is estimated 
from the cancer registry data, whereas P(t) is treated as a known quantity and is 
retrieved from the life tables of a comparable general population, usually matched to 
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the cancer patients by at least age, sex, calendar time and geographical area [15]. 
The excess hazard is derived as the difference between the estimated total hazard 
and the expected hazard. By integrating over time we obtain the cumulative excess 
hazard Λ𝐸(𝑡) as 
Λ𝐸(𝑡) = Λ
∗(𝑡) − Λ𝑃(𝑡), 
where Λ∗(𝑡) is the total cumulative hazard and Λ𝑃(𝑡) is the expected cumulative 
hazard. Until recently, the decomposition (1) and the estimation of the excess hazard 
were commonly made by assuming independence between the cancer and non-
cancer mortality processes. Pohar Perme et al. [1] argued that these two processes 
are very likely to be correlated, giving rise to an informative censoring that could 
grossly bias the results if ignored. To overcome this problem they proposed to adjust 
the continuous version of the Ederer II estimator [16] by using inverse probability of 
censoring weights [17], where the weights are the reciprocal of the individual-specific 
expected survival probabilities. Without going into much detail, the Ederer II estimator 
of Λ𝐸(𝑡) can be derived as the difference between the Nelson-Aalen estimator of 
Λ∗(𝑡) and the cumulative expected hazard of the patients still at risk at each failure. 
More details can be found in Pohar Perme et al. [1] and Rebolj Kodre and Pohar 
Perme [18]. 
 
2.2 Resampling study 
2.2.1 The data 
The population for our resampling study was extracted from four English cancer 
registries and consists of 50387 male patients who were diagnosed with colorectal 
cancer between 1996 and 2006 with follow-up until the end of 2009 and for whom we 
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had complete information on age at diagnosis, survival time, vital status, stage at 
diagnosis and deprivation quintile (based on the income domain of the Index of 
Multiple Deprivation). Table 1 summarises the data. 
The background general population mortality rates for our relative survival 
analysis were retrieved from life tables for England stratified by age, sex, calendar 
year, region and deprivation. 
 
 
 All   Patients with  
 patients  stage 1 stage 2 stage 3 stage 4 
       
Overall 50387  13.9% 32.4% 30.0% 23.7% 
       
Deaths 32267  8.6% 25.7% 30.2% 35.5% 
       
Deprivation       
   1 - least deprived 10599  15.0% 32.2% 31.2% 21.6% 
   2 10773  14.9% 32.4% 30.6% 22.1% 
   3 9914  14.0% 33.5% 29.2% 23.3% 
   4 9983  13.0% 33.0% 29.3% 24.7% 
   5 - most deprived 9118  12.4% 30.7% 29.3% 27.6% 
       
Age at diagnosis       
   Median 70.9  70.7 72.1 70.2 70.3 
   IQR (62.8,77.5)  (63,77.1) (64.1,78.2) (62.0,77.0) (61.9,77.3) 
 
Table 1. Descriptive statistics of the complete cancer registry data set used for the 
resampling study. 
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2.2.2 Missing data generation and analysis setting 
From our fully observed data set of 50387 cancer patients we created 1000 
independent random samples, each of 5000 patients. We then introduced missing 
tumour stage values. We considered two scenarios depending on whether the overall 
rate of incomplete stage information was set to around 30% (scenario A) or 50% 
(scenario B). In both scenarios the missingness was assumed to depend only on 
observed quantities, i.e. to be missing at random (MAR). Specifically, for each of the 
1000 independent resamples we proceeded as follows. 
Step 1: we randomly sampled 5000 patients from the population. 
Step 2: using a missing at random mechanism dependent on survival time, event 
indicator, age at diagnosis (linear and quadratic effect) and deprivation, we induced 
missing data on stage under two scenarios, A and B, giving around 30% and 50% 
of missing stage values respectively. See the Appendix for more details about the 
simulated missing data mechanisms. 
Step 3: we conducted a complete records analysis (CRA) and obtained stage-
specific net survival estimates at time t (t = 1, 2, …, 5 years) post diagnosis using 
the Pohar-Perme estimator. 
Step 4: we carried out multiple imputation (MI). In more detail, we used a multinomial 
logistic imputation model for stage and included the Nelson-Aalen estimate of the 
cumulative hazard, the event indicator, dummy variables for deprivation and a 
restricted cubic spline function for age at diagnosis (knots placed at the 0th, 33rd, 
67th and 100th centiles of the distribution). Other life-table variables (e.g. indicators 
for region) were initially included in the model but, since they were found to be non-
significant, we dropped them from the final model. For both scenarios A and B we 
generated 100 imputed data sets. 
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Step 5: in each of the imputed data sets we estimated stage-specific net survival at   
t = 1,...,5 years after diagnosis using the Pohar-Perme method. 
Step 6: we pooled the imputation-specific results. The MI point estimates and their 
95% confidence intervals were derived by applying the Rubin’s rules after a suitable 
transformation to improve normality and by then back transforming to the original 
scale. 
 
A complementary log-log transformation is usually recommended for predicted 
survival probabilities [19] as it maps the interval (0, 1) to (−∞, +∞). However, in the 
relative survival context the application of this transformation is sometimes 
problematic as numerical instability may arise if the probability is very close to 0 or 1. 
An additional complication is that estimates of net survival above 1 may also 
occasionally occur. In our study we faced these problems when we tried to obtain MI 
estimates for stage 1 as a few of the estimates to be transformed fell just below or 
above 1. We therefore decided to use a log transformation for stage 1 and a 
complementary log-log transformation for the other stage categories. For 
comparison, we also calculated the MI point and interval estimates using Rubin’s 
rules without a prior transformation to normality.  
Steps 1 to 6 were then repeated 1000 times. The results across these 
replications were compared to the reference values (here treated as the “true” 
values) obtained using the Pohar-Perme estimator on the fully observed population 
data. Under both scenarios we evaluated the performance of CRA and our MI 
method in terms of bias, coverage rate and average length of the 95% confidence 
intervals [20]. The bias is defined as the difference between the average of the 
estimates across the repeated samples and the reference value, while the coverage 
is the proportion of times the 95% confidence interval includes the reference value. 
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Coverage rates are considered acceptable if they are approximately not more 
than 2 standard errors away from the nominal coverage probability [20]. In our case 
the coverage rates should therefore fall approximately between 93.6% and 96.4% 
(i.e. 95% ±  2 ∗ √0.95*0.05/1000 ). 
As a rule of thumb, it is recommended that the number of imputations m 
should be at least equal to the percentage of incomplete records in the dataset. For 
example, if there are 20% of records with missing values then we should set m to at 
least 20 [11]. However, White et al. [11] and Royston and White [21] pointed out that 
in simulations studies where the interest lies in comparing statistical methods larger 
values of m are needed. In our study we therefore set m=100 but for real data 
analyses we recommend using the rule of thumb. 
All the analyses were performed using Stata 13 [22]. In particular, the Pohar-
Perme estimates were obtained using the stns command [23]. 
 
3. Results 
Table 2 displays the findings of our resampling study. The application of the Rubin’s 
rules with and without a prior normalizing transformation yielded similar results so, for 
simplicity, hereafter we only report those without the transformation. CRA led to 
severe bias and very poor coverage under both scenarios, clearly showing that this 
type of analysis should not be used when estimating stage-specific net survival from 
data with a non-trivial proportion of missing stage. We note that our MI strategy 
performed much better than CRA in terms of bias and coverage. Under scenario A, 
i.e. with around 30% of missingness, MI succeeded in recovering the missing stage 
information from the incomplete records, all empirical coverage rates being 
satisfactory and the largest relative bias being 6.4%. Some of the coverage rates 
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(especially those for stage 1) were higher than 96.4%, suggesting that the MI 
strategy may sometimes be too conservative. 
Increasing the proportion of missing values to 50% (scenario B) somehow 
worsened the performance of MI for stage 4, for which we now observed coverage 
rates as low as 84.9%. However, despite this under-coverage, MI still greatly 
outperformed CRA. Indeed, under scenario B, the coverage rates from CRA did not 
go above 8.1%. 
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   Full data   Scenario A (30% missing values)   Scenario B (50% missing values) 
 
 (reference 
 
Complete records analysis 
  
Multiple imputation 
 
 Complete records analysis 
  
Multiple imputation 
 
 value) 
 
bias rbias avL coverage 
 
bias rbias avL coverage 
 
bias rbias avL coverage 
 
bias rbias avL coverage 
                       
stage 1  
                     
S1(1)  94.50 
 
3.07 3.2% 4.09 17.6% 
 
0.03 0.0% 5.66 98.8% 
 
4.52 4.8% 3.89 2.0% 
 
-0.04 0.0% 6.60 99.5% 
S1(2)  93.63 
 
4.34 4.6% 5.32 13.6% 
 
-0.64 -0.7% 7.28 97.5% 
 
6.59 7.0% 5.17 0.4% 
 
-1.27 -1.4% 8.73 97.4% 
S1(3)  92.26 
 
5.48 5.9% 6.61 11.0% 
 
-0.84 -0.9% 8.59 97.3% 
 
8.50 9.2% 6.57 0.3% 
 
-1.77 -1.9% 10.32 95.0% 
S1(4)  90.71 
 
6.38 7.0% 8.00 13.1% 
 
-0.77 -0.9% 9.81 97.3% 
 
10.29 11.3% 8.11 0.3% 
 
-1.66 -1.8% 11.72 95.7% 
S1(5)  89.13 
 
7.21 8.1% 9.59 18.8% 
 
-0.46 -0.5% 11.15 96.7% 
 
11.86 13.3% 9.87 0.6% 
 
-1.25 -1.4% 13.18 97.1% 
                       
stage 2  
                     
S2(1)  90.03 
 
4.75 5.3% 3.37 0.1% 
 
0.14 0.2% 4.41 97.8% 
 
7.13 7.9% 3.34 0.0% 
 
0.10 0.1% 5.18 98.8% 
S2(2)  86.29 
 
6.52 7.6% 4.41 0.0% 
 
-0.41 -0.5% 5.47 96.4% 
 
10.13 11.7% 4.47 0.0% 
 
-0.85 -1.0% 6.50 95.7% 
S2(3)  82.73 
 
7.78 9.4% 5.34 0.0% 
 
-0.63 -0.8% 6.24 96.0% 
 
12.49 15.1% 5.54 0.0% 
 
-1.25 -1.5% 7.36 93.3% 
S2(4)  79.62 
 
8.66 10.9% 6.24 0.0% 
 
-0.61 -0.8% 6.92 96.0% 
 
14.25 17.9% 6.60 0.0% 
 
-1.26 -1.6% 8.07 94.2% 
S2(5)  76.97 
 
9.24 12.0% 7.25 0.0% 
 
-0.57 -0.7% 7.67 95.6% 
 
15.54 20.2% 7.77 0.0% 
 
-1.20 -1.6% 8.82 94.9% 
 
 
                     
stage 3  
                     
S3(1)  83.00 
 
5.70 6.9% 4.36 0.0% 
 
-0.69 -0.8% 5.25 95.7% 
 
8.97 10.8% 4.58 0.0% 
 
-1.09 -1.3% 6.16 94.3% 
S3(2)  71.38 
 
8.06 11.3% 5.69 0.0% 
 
-0.10 -0.1% 6.21 96.9% 
 
13.45 18.8% 6.18 0.0% 
 
-0.14 -0.2% 7.23 97.3% 
S3(3)  62.23 
 
9.00 14.5% 6.51 0.0% 
 
0.26 0.4% 6.65 96.6% 
 
15.74 25.3% 7.27 0.0% 
 
0.64 1.0% 7.69 95.3% 
S3(4)  55.91 
 
9.32 16.7% 7.10 0.0% 
 
0.40 0.7% 6.98 96.2% 
 
16.84 30.1% 8.08 0.0% 
 
0.99 1.8% 8.01 94.5% 
S3(5)  51.67 
 
9.37 18.1% 7.70 0.3% 
 
0.32 0.6% 7.37 96.6% 
 
17.35 33.6% 8.87 0.0% 
 
0.93 1.8% 8.41 94.9% 
 
 
                     
stage 4  
                     
S4(1)  37.29 
 
6.30 16.9% 7.56 7.8% 
 
0.38 1.0% 6.44 97.9% 
 
10.89 29.2% 9.85 0.6% 
 
0.88 2.4% 7.26 95.5% 
S4(2)  18.39 
 
5.05 27.5% 6.53 11.5% 
 
0.81 4.4% 5.32 94.1% 
 
9.55 51.9% 8.93 0.8% 
 
1.62 8.8% 6.15 86.6% 
S4(3)  10.66 
 
3.84 36.1% 5.51 18.7% 
 
0.68 6.4% 4.33 93.6% 
 
7.65 71.8% 7.80 1.3% 
 
1.42 13.3% 5.06 84.9% 
S4(4)  7.50 
 
3.10 41.3% 4.95 28.9% 
 
0.43 5.7% 3.77 96.3% 
 
6.33 84.4% 7.13 3.5% 
 
0.92 12.3% 4.40 90.6% 
S4(5)  5.90   2.62 44.3% 4.72 39.2%   0.25 4.2% 3.51 96.8%   5.47 92.6% 6.84 8.1%   0.55 9.3% 4.06 95.0% 
 
Table 2. Results for CRA and MI under scenarios A (30% missingness) and B (50% missingness). Sr(t) denotes net survival (%) for stage=r and time=t years 
after diagnosis (r=1,…,4; t=1,…,5). The reference values correspond to the net survival estimates obtained using the fully observed population data. The 
performance of CRA and MI are evaluated in terms of bias, percentage relative bias (rbias), average length (avL) and coverage rate of the 95% CIs. The bias 
is defined as the difference between the average of the estimates across the repeated samples and the reference value, while the coverage is the proportion 
of times the 95% confidence interval includes the reference value.
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4. Discussion 
To the best of our knowledge, this is the first study to discuss how missing values should be 
handled in the context of the non-parametric Pohar-Perme estimator. Our results are very 
encouraging. 
We focused on tumour stage at diagnosis for two reasons. Firstly, it is an important 
determinant of treatment and prognosis and so a key predictor of cancer survival. Information 
on stage is of vital importance for assessing the impact of early detection programs and for a 
better understanding of trends over time or differences in cancer survival across countries [6,7]. 
Secondly, stage is often missing for a non-trivial fraction of patients and the missingness is 
typically not completely at random. 
In this setting, the ad-hoc and yet relatively popular approach of creating an extra 
category for the missing values has been shown to lead to severe bias  [8,24]. Further, as our 
findings show, the other popular approach of estimating net survival using complete records 
results in biased estimates and poor confidence interval coverage. Complete records analysis 
should therefore be avoided for the estimation of stage-specific net survival when the 
percentage of missing stage values is non-trivial.  
Another option is needed for researchers. While multiple imputation is a natural and 
practical approach, its performance in this setting needs to be evaluated before it can be 
recommended for routine use. This is because the parametric imputation model is uncongenial 
[12] with the non-parametric Pohar-Perme estimator. Despite this, because of the practicality of 
MI, we were motivated to explore this approach by Schafer’s statement “Experience suggests 
that Bayesian MI does interact well with a variety of semi- and nonparametric estimation 
procedures” [14]. 
We specified the imputation model in a similar manner to that proposed by Falcaro et al. 
[9] for the estimation of stage-specific net survival via a flexible proportional hazards model 
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[25,26]. In line with theory [10] we used a multinomial logistic imputation model for stage and 
included (i) predictors of both the values of the incomplete variable and whether it was missing, 
(ii) the variables affecting the inverse probability of censoring weights and (iii) the outcome. For 
the latter we followed the work of White and Royston [27] and incorporated the event indicator 
and the Nelson-Aalen cumulative hazard estimate. This can easily be derived in standard 
statistical software. In Stata, for example, before carrying out the imputation we can stset the 
data and use the “sts gen H=na” command to generate a new variable H containing the Nelson-
Aalen estimate for each patient. 
Encouragingly, our MI strategy reduced the bias to a practically negligible level, and 
vastly improved confidence interval coverage. Overall, MI confidence interval coverage was 
close to, or slightly above, 95%. This is in line with the slightly conservative behaviour typically 
found with uncongenial imputation (see chapter 2 in [10]). Only for two estimates of net survival 
with tumour stage 4, under the 50%-missingness scenario, did the MI confidence interval 
coverage drop below 87%. This is because the missing data mechanism was such that, while 
50% of values were missing overall, stage 4 was the category with the highest proportion of 
missingness (around 64%). The large number of missing values meant that the impact of the 
approximation implicit in the White and Royston approach of including the Nelson-Aalen 
cumulative hazard estimate and the event indicator in the imputation model became detectable 
in a small increase in bias and corresponding reduction in confidence interval coverage.  
Our results show MI gives reliable inferences with this high proportion of missing data 
and therefore provide confidence that MI will give reliable inferences when a lower proportion of 
data are missing. They further suggest that our MI approach can be expected to perform 
reasonably well also in the non-parametric cause-specific survival setting. 
Some readers may feel that the proportion of missing stage data we chose was too high, 
given the improvement in capturing stage data in recent years. However, many researchers are 
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still interested in comparisons with earlier data. Moreover, many cancer registries in developing 
countries have far from the level of stage completeness observed in the UK, US or 
Scandinavian countries. With lower proportions of missing data, is MI worth bothering with? 
Since (i) we can’t know for sure the extent of bias in any specific case and (ii) the time and effort 
involved in MI are small in relation to gathering and cleaning the data, we would argue that MI 
should be used as a matter of routine if the percentage of missing values is not negligible. 
It is however important to stress that the specification of an imputation model needs to be 
carefully tailored for each real data set under investigation to address the particular missing data 
mechanism at hand. 
As we have commented elsewhere [8,9], it is usually implausible that stage is missing 
completely at random because its missingness is typically strongly associated with survival. The 
appropriateness of the MAR assumption is important to consider. In our setting it assumes that 
the distribution of stage, given survival and other variables, is the same whether or not it is 
observed (this interpretation of MAR is set out in [10]). This makes it a natural starting point for 
the analysis. Alongside this, in applications when a large proportion of data are missing and 
inferences are critical sensitivity analysis to plausible departures from MAR should be 
considered; some possible MI approaches are sketched in chapter 10 of [10] and will be 
developed further in future work. 
We chose a re-sampling study (as opposed to simulating the population data) because, 
as pointed out by Marshall et al. [19] and Lee and Carlin [28], it offers the advantage of working 
with data that reflect the characteristics and variability of a realistic population. Resampling 
studies share many similarities with simulation studies where the data generating mechanism is 
an explicitly specified probability model. The main difference between these two techniques is 
that in the resampling framework the analyst draws the repeated samples from a real data set 
rather than generating the data from a theoretical probability distribution. Drawing samples from 
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an existing population avoids making the inevitable simplifying assumptions about how the 
population variables should be distributed and interrelated. When, as here, our existing 
population is large (n=50387) and our random samples are about 10% of this (n=5000), we get 
valid inferences from our samples for this population when no data are missing. Then, the 
missing data mechanism is under our control and we know that it is responsible for the 
inferential biases. We can then directly assess how successful multiple imputation is in 
correcting these. Inevitably, as with all simulation studies, our results could be further 
strengthened by experience with alternative populations, cancer sites and missing data 
mechanisms. Nevertheless, we believe that our study, being based on a real complex data set, 
gives valuable insights on the performance of multiple imputation when combined with the 
Pohar-Perme method. For colorectal cancer (and cancers with similar survival profiles) it 
provides robust evidence that the widespread use of MI would give substantial, scientifically 
important, improvements to the inferences made using currently popular methods for missing 
data. Further work is planned to generalize these findings to other cancer sites. 
In passing, note that the complete population used for our resampling study was obtained 
by extracting the registry records of patients with no missing values on our key set of variables. 
We did this so to have full control on the missing data mechanism. This however means that the 
net survival estimates reported in this paper are not representative of the UK population or even 
the cancer registries from which the resampling population was extracted; but such 
representativeness was not the aim of our work. 
In conclusion, this study demonstrates that MI offers a substantial, practically important, 
improvement on complete records analysis when faced with missing data in the non-parametric 
estimation of stage-specific colorectal cancer net survival. 
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Appendix 
 
Let R denote the missing data indicator and Z be a vector of covariates. The missing values for 
tumour stage were induced with a probability generated using the model  
𝑙𝑜𝑔𝑖𝑡(𝑃(𝑅 = 1 | 𝑍))  =  𝛼 +   𝛽 T +  𝛾 D +  𝛿1 age +  𝛿2 agesq +  ∑ 𝜈𝑖 𝐼{dep = 𝑖}
5
𝑖=2
 
 
where T represents the observed survival time in years, D is the event indicator, age refers to 
standardised age at diagnosis, agesq is age squared and  𝐼{dep = 𝑖} is the indicator function 
equal 1 when dep (deprivation quintile) = i  and 0 otherwise (i = 1,…,5). The parameters were 
chosen as follows. 
(a) scenario A (30% missingness): 
𝛼 = −0.212, 𝛽 = − 0.25, 𝛾 = − 0.1 , 𝛿1 = 0.35, 𝛿2 = 0.12 , 𝜈2 = 𝜈3 = 0, 𝜈4 = 0.2 and 𝜈5 = 0.3.  
(b) scenario B (50% missingness): 
𝛼 = 0.78, 𝛽 = − 0.25, 𝛾 = − 0.1 , 𝛿1 = 0.35, 𝛿2 = 0.12 , 𝜈2 = 𝜈3 = 0, 𝜈4 = 0.2 and 𝜈5 = 0.3. 
The equation defining the missing data mechanism is a logistic model. Therefore, if for example 
we set ν5 = 0.3, this corresponds to an odds ratio of 1.35 (i.e. e
0.3) for patients living in the most 
deprived areas (dep=5) versus those living in the most affluent areas (dep=1), conditional on 
other variables being held constant. 
 
 
 
